Carcinoma of an unknown primary: Are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy? (British Journal of Cancer (2008) 97, (857-861) DOI: 10.1038/sj.bjc.6603942);Carcinoma of an unknown primary: Are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?

British Journal of Cancer

Volumn 97, Issue 7, 2007, Pages 857-861

  Massard, C ^a   Voigt, J J ^b   Laplanche, A ^a   Culine, S ^c   Lortholary, A ^d   Bugat, R ^b   Theodore, C ^a   Priou, F ^e   Kaminsky, M C ^f   Lesimple, T ^g   Pivot, X ^h   Coudert, B ⁱ   Douillard, J Y ^j   Merrouche, Y ^k   Fizazi, K ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

^c CENTRE VAL D AURELLE   (France)

^d CENTRE PAUL PAPIN   (France)

^e Centre Hospitalier la Roche/Yon   (France)

^f CENTRE ALEXIS VAUTRIN   (France)

^g CENTRE EUGÈNE MARQUIS   (France)

^h UNIVERSITY HOSPITAL OF BESANÇON   (France)

ⁱ CENTRE GEORGES FRANÇOIS LECLERC   (France)

^j CENTRE RENÉ GAUDUCHEAU   (France)

^k Institut de Cancerologie de la Loire   (France)

more..

Author keywords

c Kit; Carcinoma of an unknown primitive; EGFR; Her 2 neu overexpression; Tyrosine kinase receptor

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; IRINOTECAN; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOPSY; CANCER SURVIVAL; CARCINOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INGUINAL LYMPH NODE; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

EID: 34948816642     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604800     Document Type: Erratum

References (27)

1. Baselga J, Arteaga CL (2005) Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23(11): 2445-2459. E-pub 2005 Mar 7. Review
2. Brown ER, Shepherd FA (2005) Erlotinib in the treatment of non-small cell lung cancer. Expert Rev Anticancer Ther 5(5): 767-775. Review
3. Culine S, Kramar A, Saghatchian M, Bugat R, Lesimple T, Lortholary A, Merrouche Y, Laplanche A, Fizazi K, French Study Group on Carcinomas of Unknown Primary (2002) Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol 20(24): 4679-4683
4. Culine S, Lortholary A, Voigt JJ, Bugat R, Theodore C, Priou F, Kaminsky MC, Lesimple T, Pivot X, Coudert B, Douillard JY, Merrouche Y, Allouache J, Goupil A, Negrier S, Viala J, Petrow P, Bouzy J, Laplanche A, Fizazi K, The Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01) (2003) Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study - trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 21(18): 3479-3482
5. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351(4): 337-345
6. Fizazi K (2006) Carcinoma of an Unknown Primary Site. Taylor and Francis: New York, NY 10016, USA
7. Giaccone G (2005) Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 23(14): 3235-3242. Review
8. Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92(5): 1331-1346
9. Greco FA, Burris III HA, Litchy S, Barton JH, Bradof JE, Richards P, Scullin Jr DC, Erland JB, Morrissey LH, Hainsworth JD (2002) Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study. J Clin Oncol 20(6): 1651-1656
10. Hainsworth JD, Lennington WJ, Greco FA (2000) Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. J Clin Oncol 18(3): 632-635
11. Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20(6): 1692-1703. Review
12. Janne PA, Gurubhagavatula S, Yeap BY, Lucca J, Ostler P, Skarin AT, Fidias P, Lynch TJ, Johnson BE (2004) Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, 'Iressa') on an expanded access study. Lung Cancer 44(2): 221-230
13. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G (2002) Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3(11): 655-664. Review
14. Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353(2): 172-187. Review. No abstract available
15. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33(4): 369-385. Review
16. O'Hare T, Corbin AS, Druker BJ (2006) Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 16(1): 92-99. E-pub 2005 Dec 15. Review
17. Pavlidis N, Briassoulis E, Bai M, Fountzilas G, Agnantis N (1995) Overexpression of C-myc, Ras and C-erbB-2 oncoproteins in carcinoma of unknown primary origin. Anticancer Res 15(6B): 2563-2567
18. Pavlidis N, Fizazi K (2005) Cancer of unknown primary (CUP). Crit Rev Oncol Hematol 54(3): 243-250. Review
19. Sequist LV, Bell DW, Lynch TJ, Haber DA (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25(5): 587-595. Review
20. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2): 123-132
21. Shigematsu H, Gazdar AF (2006) Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118(2): 257-262. Review
22. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11): 783-792
23. Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T (2005) Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11(16): 5878-5885
24. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496): 1527-1537
25. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA (2005) Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353(2): 133-144. Erratum in: N Engl J Med. 2006 Oct 19;355(16):1746
26. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, Knecht R, Amellal N, Schueler A, Baselga J (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25(16): 2171-2177
27. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, Sauter G (2004) Prevalence of KIT expression in human tumors. J Clin Oncol 22(22): 4514-4522